B. Metzler Seel. Sohn & Co. Ag Arrowhead Pharmaceuticals, Inc. Transaction History
B. Metzler Seel. Sohn & Co. Ag
- $9.49 Billion
- Q2 2024
A detailed history of B. Metzler Seel. Sohn & Co. Ag transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, B. Metzler Seel. Sohn & Co. Ag holds 18,705 shares of ARWR stock, worth $362,128. This represents 0.01% of its overall portfolio holdings.
Number of Shares
18,705
Previous 18,705
-0.0%
Holding current value
$362,128
Previous $534,000
8.99%
% of portfolio
0.01%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding ARWR
# of Institutions
295Shares Held
92.3MCall Options Held
1.33MPut Options Held
549K-
Black Rock Inc. New York, NY15.7MShares$304 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.2MShares$236 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY8.89MShares$172 Million3.15% of portfolio
-
State Street Corp Boston, MA5.84MShares$113 Million0.01% of portfolio
-
Slate Path Capital LP New York, NY4.14MShares$80.1 Million2.11% of portfolio
About ARROWHEAD PHARMACEUTICALS, INC.
- Ticker ARWR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 105,849,000
- Market Cap $2.05B
- Description
- Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...